Benjamin Wu

1.7k total citations
62 papers, 1.2k citations indexed

About

Benjamin Wu is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Benjamin Wu has authored 62 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 18 papers in Molecular Biology and 17 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Benjamin Wu's work include Monoclonal and Polyclonal Antibodies Research (17 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Biosimilars and Bioanalytical Methods (12 papers). Benjamin Wu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (17 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Biosimilars and Bioanalytical Methods (12 papers). Benjamin Wu collaborates with scholars based in United States, France and Switzerland. Benjamin Wu's co-authors include Min Zhu, Sandhya Girish, René Bruno, Andreas Wolf, Colby S. Shemesh, Andrew Chow, Joy Hsu, Jessica Johnson, Christian Brandl and Patrick Twomey and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Benjamin Wu

60 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benjamin Wu United States	20	567	397	394	285	155	62	1.2k
Peter O’Gorman Ireland	23	571 1.0×	225 0.6×	654 1.7×	147 0.5×	76 0.5×	72	1.8k
K. C. Anderson United States	20	440 0.8×	453 1.1×	670 1.7×	228 0.8×	112 0.7×	38	1.6k
Zhaoqin Huang China	19	691 1.2×	273 0.7×	291 0.7×	281 1.0×	358 2.3×	52	1.3k
Michael J. Guarino United States	16	964 1.7×	333 0.8×	428 1.1×	380 1.3×	403 2.6×	63	1.5k
Antje Lebrecht Germany	23	610 1.1×	215 0.5×	407 1.0×	181 0.6×	147 0.9×	58	1.4k
Teresa Amaral Germany	24	893 1.6×	275 0.7×	498 1.3×	111 0.4×	225 1.5×	82	1.4k
K. Martin Kortüm Germany	25	901 1.6×	240 0.6×	1.0k 2.6×	216 0.8×	103 0.7×	103	1.8k
Francesco Sabbatino Italy	23	992 1.7×	479 1.2×	594 1.5×	78 0.3×	278 1.8×	96	1.9k
Johanna Louhimo Finland	29	770 1.4×	179 0.5×	639 1.6×	128 0.4×	348 2.2×	57	1.9k

Countries citing papers authored by Benjamin Wu

Since Specialization

Citations

This map shows the geographic impact of Benjamin Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Wu more than expected).

Fields of papers citing papers by Benjamin Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Wu. The network helps show where Benjamin Wu may publish in the future.

Co-authorship network of co-authors of Benjamin Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Wu. A scholar is included among the top collaborators of Benjamin Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Wu. Benjamin Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chan, Phyllis, Nathalie Gosselin, Mathilde Marchand, et al.. (2025). Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer. CPT Pharmacometrics & Systems Pharmacology. 14(4). 726–737. 2 indexed citations

Grimaldi, Christine, Susan Richards, Daniel Baltrukonis, et al.. (2025). IQ Survey Results on Current Industry Practices—Part 1: Immunogenicity Risk Assessment. Clinical Pharmacology & Therapeutics. 117(6). 1596–1604.

Vora, Bianca, et al.. (2024). Integrating real‐world data and machine learning: A framework to assess covariate importance in real‐world use of alternative intravenous dosing regimens for atezolizumab. Clinical and Translational Science. 17(11). e70077–e70077. 1 indexed citations

Quarmby, Valerie, James A. Zanghi, Coen Bernaards, et al.. (2024). Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency on Reported Anti-drug Antibody Incidence Rates. The AAPS Journal. 26(4). 84–84. 3 indexed citations

Shemesh, Colby S., Phyllis Chan, Mathilde Marchand, et al.. (2023). Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework. Clinical Pharmacology & Therapeutics. 114(3). 644–651. 4 indexed citations

Krishnan, Sreenath M., Lena E. Friberg, François Mercier, et al.. (2023). Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical Pharmacology & Therapeutics. 113(4). 851–858. 8 indexed citations

Bruno, René, Mathilde Marchand, Kenta Yoshida, et al.. (2023). Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical Cancer Research. 29(6). 1047–1055. 13 indexed citations

Vora, Bianca, et al.. (2023). Applications of Advanced Natural Language Processing for Clinical Pharmacology. Clinical Pharmacology & Therapeutics. 115(4). 786–794. 8 indexed citations

Yoshida, Kenta, Phyllis Chan, Mathilde Marchand, et al.. (2022). Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study. The AAPS Journal. 24(3). 58–58. 4 indexed citations

10.

Marchand, Mathilde, Rong Zhang, Phyllis Chan, et al.. (2021). Time-dependent population PK models of single-agent atezolizumab in patients with cancer. Cancer Chemotherapy and Pharmacology. 88(2). 211–221. 24 indexed citations

11.

Chan, Phyllis, Mathilde Marchand, Kenta Yoshida, et al.. (2021). Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework. CPT Pharmacometrics & Systems Pharmacology. 10(10). 1171–1182. 24 indexed citations

12.

Morrissey, Kari M., Mathilde Marchand, Hina Patel, et al.. (2019). Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemotherapy and Pharmacology. 84(6). 1257–1267. 62 indexed citations

13.

Tardivon, Coralie, René Bruno, Benjamin Wu, et al.. (2019). Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow‐Up. Clinical Pharmacology & Therapeutics. 106(4). 810–820. 36 indexed citations

14.

Chen, Ping, Benjamin Wu, Per Olsson, et al.. (2017). Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. Clinical Pharmacokinetics. 57(1). 71–85. 7 indexed citations

15.

Edson, Katheryne Z., et al.. (2016). Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing. Kidney International Reports. 1(1). 24–33. 17 indexed citations

16.

Subramanian, Raju, Xiaochun Zhu, M. Benjamin Hock, et al.. (2016). Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis. Clinical Pharmacokinetics. 56(2). 179–192. 21 indexed citations

17.

Zhu, Min, Benjamin Wu, Christian Brandl, et al.. (2016). Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clinical Pharmacokinetics. 55(10). 1271–1288. 157 indexed citations

18.

Kaufman, Peter A., Gilles Freyer, Margaret Kemeny, et al.. (2015). A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer. Open Repository and Bibliography (University of Liège). 1 indexed citations

19.

Clarke, Janet, Susanne Pippig, Amita Joshi, et al.. (2004). Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regulatory Toxicology and Pharmacology. 40(3). 219–226. 47 indexed citations

20.

Green, Carol E., et al.. (2001). Analysis of 2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Journal of Chromatography A. 924(1-2). 471–481. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact